LIMN Stock Climbs 36% amid 20M+ Share Registration and Q2 10-Q Delay

Introduction

Liminatus Pharma Inc is a clinical-stage biopharmaceutical company developing second-generation CD47 antibodies for solid tumors. Headquartered at 3524 Silverside Road, Suite 35B, Wilmington, Delaware 19810, the company trades on NASDAQ under the ticker LIMN. As of August 22, 2025, the share price stood at $3.78, reflecting a 35.97% increase on a trading volume of 7,115,978 shares.

Ticker	Exchange	Price	Change (%)	Volume
LIMN	NASDAQ	$3.78	+35.97	7,115,978

Corporate Structure

Liminatus Pharma emerged in June 2025 from a merger with Iris Acquisition Corp, a SPAC valued at $276 million, and adopted its current name following the transaction. The company’s leadership team and advisory board include professionals with expertise in immuno-oncology research, clinical development, and capital markets. While the exact number of employees is not publicly disclosed, LinkedIn profiles suggest a workforce experienced in therapeutic antibody development, regulatory affairs, and biotechnology finance.

Biopharmaceuticals by little plant

Recent Developments

On August 13, 2025, Liminatus Pharma filed a prospectus (Rule 424(b)(3)) registering 20,454,961 shares of common stock for resale by existing security holders. The prospectus includes details on share allocations from merger consideration, convertible founder shares, PIPE equity subscriptions, private warrant exercises, deferred underwriting fees, and a settlement agreement. On August 14, 2025, the company submitted a Form 8-K reporting under Items 7.01 and 9.01. On August 15, 2025, Liminatus notified the SEC of a delay in filing its Form 10-Q for the quarter ended June 30, 2025, committing to file the report by September 1, 2025.

Financial and Strategic Analysis

The Form NT 10-Q notification does not include detailed financial metrics but highlights challenges in finalizing quarterly statements for review and approval. The Rule 424(b)(3) prospectus suggests potential selling pressure from registered shares and outlines risks related to liquidity and share-price volatility. As of July 23, 2025, the last reported sales price was $6.47 per share, with public warrants trading at $0.2775. Warrants have an exercise price of $11.50, which may limit conversions until market prices increase. Management has indicated ongoing efforts to enhance internal reporting processes and meet regulatory deadlines.

Market Position and Industry Context

Within the immuno-oncology sector, Liminatus Pharma’s CD47 candidates compete among companies pursuing immune-checkpoint therapies. The June 2025 SPAC merger has provided access to NASDAQ liquidity and public capital markets. Key industry considerations include navigating regulatory approval pathways, scaling manufacturing, and demonstrating clinical efficacy. The global market for immune-modulating cancer treatments continues to expand, supported by ongoing clinical trials and combination-therapy strategies.

tl;dr

On August 13–15, 2025, Liminatus Pharma filed a 424(b)(3) prospectus registering over 20 million shares for resale; a Form 8-K under Items 7.01 and 9.01; and an NT 10-Q notification citing a delay for the quarter ended June 30, 2025. Common stock closed at $3.78 on August 22, 2025, with public warrants at $0.2775 as of July 23, 2025. The $11.50 warrant exercise price may defer conversion. The company plans to file the 10-Q by September 1, 2025, and is enhancing internal reporting processes.